公开(公告)号：US20170260141A1

公开(公告)日：2017-09-14

申请号：US15529290

申请日：2015-11-25

Applicant: University of Kansas

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D223/16 ,  C07D209/44

CPC classification number: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

公开(公告)号：US20160257685A1

公开(公告)日：2016-09-08

申请号：US15156887

申请日：2016-05-17

Applicant: University of Kansas ,  The Scripps Research Institute

Inventor： Jeffrey Aube ,  Laura Bohn ,  Thomas Edward Prisinzano ,  Frank John Schoenen ,  Kevin J. Frankowski

IPC: C07D471/14 ,  C07D401/14 ,  C07D409/14 ,  C07D401/04 ,  C07D471/04 ,  C07D405/14

CPC classification number: C07D471/14 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  A61K2300/00

Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.

Abstract translation: 本发明是可用于治疗乙醇使用障碍戒断，焦虑和/或抑郁，精神分裂症，躁狂症或创伤后应激障碍的选择性κ阿片受体效应物或其药学上可接受的盐。

公开(公告)号：US10829453B2

公开(公告)日：2020-11-10

申请号：US16179637

申请日：2018-11-02

Applicant: University of Kansas ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

公开(公告)号：US20190300486A1

公开(公告)日：2019-10-03

申请号：US16179637

申请日：2018-11-02

Applicant: University of Kansas ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

公开(公告)号：US10118896B2

公开(公告)日：2018-11-06

申请号：US15529290

申请日：2015-11-25

Applicant: University of Kansas

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

公开(公告)号：US09540375B2

公开(公告)日：2017-01-10

申请号：US15156887

申请日：2016-05-17

Applicant: University of Kansas ,  The Scripps Research Institute

Inventor： Jeffrey Aube ,  Laura Bohn ,  Thomas Edward Prisinzano ,  Frank John Schoenen ,  Kevin J. Frankowski

IPC: C07D403/14 ,  C07D249/12 ,  C07D471/14 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04

CPC classification number: C07D471/14 ,  A61K31/4196 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4985 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D471/04 ,  A61K2300/00

Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.

Abstract translation: 本发明是可用于治疗乙醇使用障碍戒断，焦虑和/或抑郁，精神分裂症，躁狂症或创伤后应激障碍的选择性κ阿片受体效应物或其药学上可接受的盐。